Q2 2021 DrugInsights

IngenioRx’s DrugInsights offers a quarterly summary of new molecular entities, formulations, and indications approved by the Food and Drug Administration (FDA). In this second edition, we continue to closely monitor the FDA landscape to provide our audiences with an understanding of the current drug and biologic market.